Back

A pre-specified, participant-level pooled analysis of PARAGON-HF and PARAGLIDE-HF

21 May 2023 (11:27 - 11:39)
Organised by: Logo
Congress Presentation Part of: Late breaking clinical trials: medical therapy Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Muthiah Vaduganathan

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
PARAGLIDEHF: Sacubitril/Valsartan versus valsartan on changes in NTproBNP, safety, and tolerability in patients with EF>40% stabilized after a WHF Event
Doctor R. Mentz (Durham, US)
Slides Video
Presentation thumbnail
STEP HFpEF trial design and baseline characteristics
Doctor M. Kosiborod (Kansas City, US)
Slides Video
Presentation thumbnail
DAPA-RESIST clinical trial - Dapagliflozin versus metolazone in heart failure with diuretic resistance
Doctor R. Campbell (Glasgow, GB)
Slides Video
Presentation thumbnail
Verinurad plus allopurinol for heart failure with preserved ejection fraction: results from the AMETHYST randomized controlled trial
Professor A. Voors (Groningen, NL)
Slides Video

Access the full session

Session thumbnail
Late breaking clinical trials: medical therapy
Video

The Event

Event poster

Heart Failure 2023

21 May 2023 11:27 CET
You may be interested in
thumbnail
Congress Presentation
PARAGLIDEHF: Sacubitril/Valsartan versus valsartan on changes in NTproBNP, safety, and tolerability in patients with EF>40% stabilized after a WHF Event
thumbnail
Congress Session
Late breaking clinical trials: medical therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources